280 related articles for article (PubMed ID: 24642271)
1. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.
Selvaraj N; Budka JA; Ferris MW; Jerde TJ; Hollenhorst PC
Mol Cancer; 2014 Mar; 13():61. PubMed ID: 24642271
[TBL] [Abstract][Full Text] [Related]
2. RAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites.
Hollenhorst PC
Small GTPases; 2012; 3(3):154-8. PubMed ID: 22653334
[TBL] [Abstract][Full Text] [Related]
3. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
4. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
5. Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells.
Strittmatter BG; Jerde TJ; Hollenhorst PC
PLoS Genet; 2021 Jul; 17(7):e1009708. PubMed ID: 34314419
[TBL] [Abstract][Full Text] [Related]
6. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
7. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.
Hollenhorst PC; Ferris MW; Hull MA; Chae H; Kim S; Graves BJ
Genes Dev; 2011 Oct; 25(20):2147-57. PubMed ID: 22012618
[TBL] [Abstract][Full Text] [Related]
9. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
10. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; LeKaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):E3506-15. PubMed ID: 23918374
[TBL] [Abstract][Full Text] [Related]
11. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
Oh YT; Yue P; Zhou W; Balko JM; Black EP; Owonikoko TK; Khuri FR; Sun SY
J Biol Chem; 2012 Jan; 287(1):257-267. PubMed ID: 22065586
[TBL] [Abstract][Full Text] [Related]
13. Characterization of KRAS rearrangements in metastatic prostate cancer.
Wang XS; Shankar S; Dhanasekaran SM; Ateeq B; Sasaki AT; Jing X; Robinson D; Cao Q; Prensner JR; Yocum AK; Wang R; Fries DF; Han B; Asangani IA; Cao X; Li Y; Omenn GS; Pflueger D; Gopalan A; Reuter VE; Kahoud ER; Cantley LC; Rubin MA; Palanisamy N; Varambally S; Chinnaiyan AM
Cancer Discov; 2011 Jun; 1(1):35-43. PubMed ID: 22140652
[TBL] [Abstract][Full Text] [Related]
14. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells.
Plotnik JP; Budka JA; Ferris MW; Hollenhorst PC
Nucleic Acids Res; 2014 Oct; 42(19):11928-40. PubMed ID: 25294825
[TBL] [Abstract][Full Text] [Related]
15. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
16. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration.
Yadav V; Denning MF
Mol Carcinog; 2011 May; 50(5):346-52. PubMed ID: 21480388
[TBL] [Abstract][Full Text] [Related]
17. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Brzezianska E; Pastuszak-Lewandoska D
Front Biosci (Landmark Ed); 2011 Jan; 16(2):422-39. PubMed ID: 21196179
[TBL] [Abstract][Full Text] [Related]
18. Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway.
Lee HY; Crawley S; Hokari R; Kwon S; Kim YS
Int J Oncol; 2010 Apr; 36(4):941-53. PubMed ID: 20198339
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
20. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
